Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Rhea-AI Summary

Citius Pharmaceuticals (NASDAQ:CTXR) reported its fiscal Q3 2025 results and provided updates on its transition to a commercial organization. The company secured $12.5 million in gross financings during Q3, with an additional $9 million raised by Citius Oncology in July 2025.

Key financial metrics include a net loss of $9.2 million ($0.80 per share), reduced from $10.6 million in Q3 2024. R&D expenses decreased to $1.6 million from $2.8 million year-over-year, while G&A expenses declined to $4.4 million from $4.8 million. The company ended the quarter with $6.1 million in cash.

Citius is preparing for the U.S. launch of LYMPHIR™ in Q4 2025 for cutaneous T-cell lymphoma treatment, having completed commercial-scale manufacturing, labeling, packaging, and distribution agreements.

Positive

• None.

Negative

• Significant ongoing net losses of $9.2M in Q3
• Low cash position of $6.1M relative to operational needs
• Continued reliance on external financing through equity and debt
• Stock-based compensation remains high at $2.7M

Insights

Biopharmaceutical Financial Analyst

Citius secures $21.5M in capital while reducing losses, preparing for critical Q4 2025 LYMPHIR commercial launch in CTCL.

Citius Pharmaceuticals' fiscal Q3 2025 results reveal a company at a pivotal inflection point, transitioning from development to commercialization with its lead asset LYMPHIR. The company has strategically secured $21.5 million in gross financing through multiple channels ($12.5M in Q3 plus $9M in July through Citius Oncology), with potential for an additional $9.8 million if June 2025 warrants are exercised. This capital infusion appears timely as Citius prepares for LYMPHIR's Q4 2025 commercial launch.

The financial metrics show improved capital efficiency with R&D expenses decreasing 43% year-over-year to $1.6 million, while G&A expenses modestly declined by 8% to $4.4 million. Net losses narrowed to $9.2 million ($0.80 per share) from $10.6 million ($1.57 per share) in the prior-year period. However, with only $6.1 million in cash as of June 30 (pre-July financing), cash runway remains a critical concern despite the recent capital raises.

The LYMPHIR launch represents Citius' potential transformation into a revenue-generating entity, addressing an underserved population with cutaneous T-cell lymphoma. The company has completed key pre-launch activities including commercial-scale manufacturing, labeling, packaging, and distribution agreements. Meanwhile, Mino-Lok remains in the pipeline with ongoing FDA discussions, though its timeline appears secondary to the imminent LYMPHIR commercialization.

The recent reverse stock split (implied by the adjusted per-share figures) and multiple capital raises suggest financial challenges, but the strategic focus on commercialization rather than continued R&D spending indicates management is prioritizing the transition to becoming a commercial-stage company. The next two quarters will be decisive as Citius executes its LYMPHIR launch strategy with its newly secured capital.

$12.5 million in gross financings raised during the quarter, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive successful market introduction

CRANFORD, N.J., Aug. 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for its fiscal third quarter ended June 30, 2025, and provided a business update.

"During the third quarter, Citius advanced its strategic priorities, and we believe we are now operationally positioned to transition from a development-stage enterprise to a fully integrated commercial organization. Final preparations are underway by our oncology subsidiary for the planned U.S. launch of LYMPHIR™ in the fourth quarter of 2025," said Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals.

"In June 2025, we completed a $6 million registered direct offering, with the potential for an additional $9.8 million upon full warrant exercise, to fund commercialization activities and corporate operations. In July 2025, Citius Oncology further strengthened its capital position with $9 million in gross proceeds from a public offering. These financings, any proceeds we might receive from exercise of the June 2025 warrants and other capital raising activities during the quarter, together with the completion of major launch-enabling activities including commercial-scale manufacturing, labeling, packaging, and distribution services agreements with leading specialty pharmaceutical partners indicate we are well-prepared to deliver LYMPHIR to patients with cutaneous T-cell lymphoma, an underserved population in need of new treatment options. At the same time, we remain focused on advancing Mino-Lok and continue to engage with the U.S. Food and Drug Administration as we evaluate the best path forward for this potentially transformative antibiotic lock solutions for patients with catheter-related bloodstream infections," added Mazur.      

FISCAL THIRD QUARTER 2025 FINANCIAL RESULTS:

• R&D expenses were $1.6 million for the quarter ended June 30, 2025, compared to $2.8 million for the quarter ended June 30, 2024;
• G&A expenses were $4.4 million for the quarter ended June 30, 2025, as compared to $4.8 million for the quarter ended June 30, 2024;
• Stock-based compensation expense was $2.7 million for the quarter ended June 30, 2025, as compared to $3.1 million for the quarter ended June 30, 2024;
• Net loss was $9.2 million, or ($0.80) per share, for the quarter ended June 30, 2025, as compared to a net loss of $10.6 million, or ($1.57) per share, for the quarter ended June 30, 2024, as adjusted for the reverse stock split;
• At June 30, 2025, Citius Pharma had cash and cash equivalents of $6.1 million available to fund its operations. During the nine months ended June 30, 2025, the Company received net proceeds of $16.5 million from the issuance of equity and $1 million from the issuance of a note payable; and,
• On July 17, 2025, Citius Oncology completed a public offering generating net proceeds of approximately $7.4 million, after deducting placement agent fees and other offering expenses.

For a complete discussion of our financial results, please refer to our Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed today with the SEC and available at www.sec.gov.

About Citius Pharmaceuticals, Inc.

Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR™, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. Citius Pharma owns 84% of Citius Oncology. For more information, please visit www.citiuspharma.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our need for substantial additional funds and our ability to raise additional money to fund our operations beyond September 2025 and for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR, including covering the costs of licensing payments, product manufacturing and other third-party goods and services, through our majority-owned subsidiary and any of our other product candidates that may be approved by the FDA; our ability to maintain compliance with Nasdaq's continued listing standards; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market, economic and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC  filings which are available on the SEC's website at www.sec.gov, including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, as amended on January 27, 2025, Citius Pharma's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 12, 2025, and as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Contact:

Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

Media Contact:

STiR-communications
Greg Salsburg
Greg@STiR-communications.com 

-- Financial Tables Follow –

 

CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
		June 30,				September 30,
		2025				2024
ASSETS
Current Assets:
Cash and cash equivalents		$	6,089,126			$	3,251,880
Inventory			17,208,967				8,268,766
Prepaid expenses			1,313,176				2,700,000
Total Current Assets			24,611,269				14,220,646
Operating lease right-of-use asset, net			880,732				246,247
Deposits			38,062				38,062
In-process research and development			92,800,000				92,800,000
Goodwill			9,346,796				9,346,796
Total Other Assets			102,184,858				102,184,858
Total Assets		$	127,676,859			$	116,651,751
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		$	10,094,042			$	4,927,211
License payable			28,400,000				28,400,000
Accrued expenses			8,523,675				17,027
Accrued compensation			3,710,041				2,229,018
Note payable			1,000,000				-
Operating lease liability			114,694				241,547
Total Current Liabilities			51,842,452				35,814,803
Deferred tax liability			7,506,520				6,713,800
Operating lease liability - noncurrent			766,957				21,318
Total Liabilities			60,115,929				42,549,921
Commitments and Contingencies
Stockholders' Equity:
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding			-				-
Common stock - $0.001 par value; 250,000,000 and 16,000,000 shares authorized; 14,475,029 and 7,247,243 shares issued and outstanding at June 30, 2025 and September 30, 2024, respectively			14,475				7,247
Additional paid-in capital			295,888,916				271,440,421
Accumulated deficit			(230,844,841)				(201,370,218)
Total Citius Pharmaceuticals, Inc. Stockholders' Equity			65,058,550				70,077,450
Non-controlling interest			2,502,380				4,024,380
Total Equity			67,560,930				74,101,830
Total Liabilities and Equity		$	127,676,859			$	116,651,751
Reflects a 1-for-25 reverse stock split effective November 25, 2024.

 

CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2025 AND 2024 (Unaudited)
		Three Months Ended								Nine Months Ended
		June 30,				June 30,				June 30,				June 30,
		2025				2024				2025				2024
Revenues		$	—			$	—			$	—			$	—
Operating Expenses
Research and development			1,621,325				2,763,865				7,514,888				8,991,673
General and administrative			4,447,008				4,808,551				14,626,882				12,755,190
Stock-based compensation – general and administrative			2,719,674				3,061,763				7,946,529				9,198,340
Total Operating Expenses			8,788,007				10,634,179				30,088,299				30,945,203
Operating Loss			(8,788,007)				(10,634,179)				(30,088,299)				(30,945,203)
Other Income (Expense)
Interest income			20,637				204,843				56,658				640,686
Gain on sale of New Jersey net operating losses			—				—				—				2,387,842
Interest expense			(172,262)				—				(172,262)				—
Total Other Income (Expense)			(151,625)				204,843				(115,604)				3,028,528
Loss before Income Taxes			(8,939,632)				(10,429,336)				(30,203,903)				(27,916,675)
Income tax expense			264,240				144,000				792,720				432,000
Net Loss			(9,203,872)				(10,573,336)				(30,996,623)				(28,348,675)
Deemed dividend on warrant extension			—				321,559				—				321,559
Net loss attributable to non-controlling interest			414,000				—				1,522,000				—
Net loss applicable to common stockholders		$	(8,789,872)			$	(10,894,895)			$	(29,474,623)			$	(28,670,234)
Net Loss Per Share - Basic and Diluted		$	(0.80)			$	(1.57)			$	(3.27)			$	(4.37)
Weighted Average Common Shares Outstanding
Basic and diluted			11,006,896				6,954,278				9,020,356				6,557,892
Reflects a 1-for-25 reverse stock split effective November 25, 2024.

 

CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED JUNE 30, 2025 AND 2024 (Unaudited)
		2025				2024
Cash Flows From Operating Activities:
Net loss		$	(30,996,623)			$	(28,348,675)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense			7,946,529				9,198,340
Issuance of common stock for services			—				284,175
Amortization of operating lease right-of-use asset			152,212				154,494
Depreciation			—				1,432
Deferred income tax expense			792,720				432,000
Changes in operating assets and liabilities:
Inventory			(8,940,201)				—
Prepaid expenses			1,386,824				(2,205,091)
Accounts payable			5,166,831				(1,263,998)
Accrued expenses			8,506,648				74,185
Accrued compensation			1,481,023				(454,315)
Operating lease liability			(167,911)				(161,234)
Net Cash Used In Operating Activities			(14,671,948)				(22,288,687)
Cash Flows From Financing Activities:
Net proceeds from common stock offerings			16,509,194				13,718,951
Proceeds from sale of Series A preferred stock			100				—
Redemption of Series A preferred stock			(100)				—
Proceeds from note payable and advance from employee			1,300,000				—
Repayment of advance from employee			(300,000)				—
Net Cash Provided By Financing Activities			17,509,194				13,718,951
Net Change in Cash and Cash Equivalents			2,837,246				(8,569,736)
Cash and Cash Equivalents - Beginning of Period			3,251,880				26,480,928
Cash and Cash Equivalents - End of Period		$	6,089,126			$	17,911,192
Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:
Operating lease right-of-use asset and liability recorded		$	786,697			$	—

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2025-financial-results-and-provides-business-update-302528078.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

What were Citius Pharmaceuticals (CTXR) Q3 2025 financial results?

Citius reported a net loss of $9.2 million ($0.80 per share), with R&D expenses of $1.6 million and G&A expenses of $4.4 million. The company had $6.1 million in cash at quarter-end.

When is CTXR planning to launch LYMPHIR?

Citius Pharmaceuticals plans to launch LYMPHIR in the fourth quarter of 2025 for treating cutaneous T-cell lymphoma patients.

How much funding did Citius Pharmaceuticals raise in Q3 2025?

Citius raised $12.5 million in gross financings during Q3 2025, including a $6 million registered direct offering with potential for additional $9.8 million from warrant exercise.

What is the status of Citius Pharmaceuticals' commercial preparation?

Citius has completed major launch-enabling activities including commercial-scale manufacturing, labeling, packaging, and distribution services agreements with specialty pharmaceutical partners.

How much additional funding did Citius Oncology secure in July 2025?

Citius Oncology completed a public offering in July 2025, generating $7.4 million in net proceeds ($9 million gross) after deducting placement agent fees and expenses.